Literature DB >> 27052152

Cyclopropanyldehydrocostunolide LJ attenuates high glucose-induced podocyte injury by suppressing RANKL/RANK-mediated NF-κB and MAPK signaling pathways.

Xiao-Wen Chen1, Wen-Ting Liu1, Yu-Xian Wang2, Wen-Jing Chen1, Hong-Yu Li1, Yi-Hua Chen1, Xiao-Yan Du1, Fen-Fen Peng1, Wei-Dong Zhou1, Zhao-Zhong Xu3, Hai-Bo Long4.   

Abstract

AIMS: The aim of this research was to investigate the effects of cyclopropanyldehydrocostunolide (also named LJ), a derivative of sesquiterpene lactones (SLs), on high glucose (HG)-induced podocyte injury and the associated molecular mechanisms.
METHODS: Differentiated mouse podocytes were incubated in different treatments. The migration and albumin filtration of podocytes were examined by Transwell filters. The protein and mRNA levels of MCP-1 were measured using enzyme-linked immunosorbent assay (ELISA) and quantitative real-time PCR (q-PCR). Protein expression and phosphorylation were detected by western blot, and the nuclear translocation of NF-κB was performed with a confocal microscope. The gene expression of the receptor activator for NF-κB (RANK) was silenced by small interfering RNA (siRNA).
RESULTS: Our results showed that HG enhanced migration, albumin filtration and MCP-1 expression in podocytes. At the molecular level, HG promoted the phosphorylation of NF-κB/p65, IKKβ, IκBα, mitogen-activated protein kinase (MAPK) and the nuclear translocation of p65. LJ reversed the effects of HG in a dose-dependent manner. Furthermore, our data provided the first demonstration that the receptor activator for NF-κB ligand (RANKL) and its cognate receptor RANK were overexpressed in HG-induced podocytes and were downregulated by LJ. RANK siRNA also attenuated HG-induced podocyte injury and markedly inhibited the activation of NF-κB and MAPK signaling pathways.
CONCLUSIONS: LJ attenuates HG-induced podocyte injury by suppressing RANKL/RANK-mediated NF-κB and MAPK signaling pathways.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  LJ; Mitogen-activated protein kinase; NF-κB; Receptor activator for NF-κB; Receptor activator for NF-κB ligand

Mesh:

Substances:

Year:  2016        PMID: 27052152     DOI: 10.1016/j.jdiacomp.2016.03.013

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  6 in total

1.  EDA2R mediates podocyte injury in high glucose milieu.

Authors:  Xiqian Lan; Vinod Kumar; Alok Jha; Rukhsana Aslam; Haichao Wang; Kehong Chen; Yueming Yu; Weimei He; Feilan Chen; Huairong Luo; Ashwani Malhotra; Pravin C Singhal
Journal:  Biochimie       Date:  2020-04-15       Impact factor: 4.079

2.  Digoxin Attenuates Receptor Activation of NF-κB Ligand-Induced Osteoclastogenesis in Macrophages.

Authors:  Kimihiro Igari; Matthew J Kelly; Dai Yamanouchi
Journal:  J Vasc Res       Date:  2019-05-14       Impact factor: 1.934

3.  Metadherin facilitates podocyte apoptosis in diabetic nephropathy.

Authors:  Wen-Ting Liu; Fen-Fen Peng; Hong-Yu Li; Xiao-Wen Chen; Wang-Qiu Gong; Wen-Jing Chen; Yi-Hua Chen; Pei-Lin Li; Shu-Ting Li; Zhao-Zhong Xu; Hai-Bo Long
Journal:  Cell Death Dis       Date:  2016-11-24       Impact factor: 8.469

Review 4.  The Role of Chemokines and Chemokine Receptors in Diabetic Nephropathy.

Authors:  Ting-Ting Chang; Jaw-Wen Chen
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 5.923

Review 5.  A Review on Antidiabetic Activity of Centaurea spp.: A New Approach for Developing Herbal Remedies.

Authors:  Samaneh Fattaheian-Dehkordi; Reza Hojjatifard; Mina Saeedi; Mahnaz Khanavi
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-05       Impact factor: 2.629

6.  Transforming growth factor-β1-induced podocyte injury is associated with increased microRNA-155 expression, enhanced inflammatory responses and MAPK pathway activation.

Authors:  Xintong Zheng; Qiuhong Zhong; Xu Lin; Xianjun Gu; Xiaoyan Ling; Zhao Liang; Qing Qin; Xiuri Du
Journal:  Exp Ther Med       Date:  2021-04-14       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.